Advertisement

Topics

Axis Biotec Announces the Construction of an Innovative Tobacco-Based Biopharmaceutical Expression and Pilot Manufacturing Facility in Brazil

08:51 EDT 20 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Construction will begin this summer on a state-of-the-art biopharmaceutical lab and pilot production facility in Rio de Janeiro that will support the development of key biosimilar and biobetter protein drugs for the Brazilian ma...

Other Sources for this Article

Axis Biotec Brasil
Lorena Diniz, +55 21 2141-7791
Project Manager
lorena.diniz@axisbiotec.com.br

NEXT ARTICLE

More From BioPortfolio on "Axis Biotec Announces the Construction of an Innovative Tobacco-Based Biopharmaceutical Expression and Pilot Manufacturing Facility in Brazil"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antiretroviral therapy
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...